Cerebrospinal fluid as a liquid biopsy for molecular characterization of brain metastasis in patients with non-small cell lung cancer

• DOI: 10.1016/j.lungcan.2023.107292
• Publication Date: 2023-07-03T21:47:14Z
• Authors: Georgios Tsakonas; Vasisht Tadigotla; Sudipto K. Chakra...; Giuseppe Stragliotto; Dalin Chan; Rolf Lewensohn; Wei Yu; Johan K. Skog; Per Hydbring; Simon Ekman
• Keywords: Lung Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Mutation; Liquid Biopsy; Humans; 3. Good health

Non-small cell lung cancer (NSCLC) with brain metastases (BM) is a challenging clinical issue with poor prognosis. No data exist regarding extensive genetic analysis of cerebrospinal fluid (CSF) and its correlation to associated tumor compartments.We designed a study across multiple NSCLC patients with matched material from four compartments; primary tumor, BM, plasma and CSF. We performed enrichment-based targeted next-generation sequencing analysis of ctDNA and exosomal RNA in CSF and plasma and compared the outcome with the solid tumor compartments.An average of 105 million reads per sample was generated with fractions of mapped reads exceeding 99% in all samples and with a mean coverage above 10,000x. We observed a high degree of overlap in variants between primary lung tumor and BM. Variants specific for the BM/CSF compartment included in-frame deletions in AR, FGF10 and TSC1 and missense mutations in HNF1a, CD79B, BCL2, MYC, TSC2, TET2, NRG1, MSH3, NOTCH3, VHL and EGFR.Our approach of combining ctDNA and exosomal RNA analyses in CSF presents a potential surrogate for BM biopsy. The specific variants that were only observed in the CNS compartments could serve as targets for individually tailored therapies in NSCLC patients with BM.